- Home
- STG vs BMEA Comparison
STG vs BMEA Comparison
Compare STG & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- BMEA
- Stock Information
- Founded
- STG 2003
- BMEA 2017
- Country
- STG China
- BMEA United States
- Employees
- STG N/A
- BMEA N/A
- Industry
- STG Other Consumer Services
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- STG Real Estate
- BMEA Health Care
- Exchange
- STG Nasdaq
- BMEA Nasdaq
- Market Cap
- STG 70.3M
- BMEA 65.8M
- IPO Year
- STG 2018
- BMEA 2021
- Fundamental
- Price
- STG $5.43
- BMEA $1.81
- Analyst Decision
- STG
- BMEA Strong Buy
- Analyst Count
- STG 0
- BMEA 10
- Target Price
- STG N/A
- BMEA $22.30
- AVG Volume (30 Days)
- STG 4.7K
- BMEA 5.2M
- Earning Date
- STG 08-15-2025
- BMEA 07-30-2025
- Dividend Yield
- STG N/A
- BMEA N/A
- EPS Growth
- STG N/A
- BMEA N/A
- EPS
- STG 3.09
- BMEA N/A
- Revenue
- STG $269,356,990.00
- BMEA N/A
- Revenue This Year
- STG N/A
- BMEA N/A
- Revenue Next Year
- STG N/A
- BMEA N/A
- P/E Ratio
- STG $1.76
- BMEA N/A
- Revenue Growth
- STG N/A
- BMEA N/A
- 52 Week Low
- STG $4.25
- BMEA $1.29
- 52 Week High
- STG $11.06
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- STG 49.16
- BMEA 44.35
- Support Level
- STG $6.05
- BMEA $2.24
- Resistance Level
- STG $6.23
- BMEA $3.08
- Average True Range (ATR)
- STG 0.35
- BMEA 0.40
- MACD
- STG -0.07
- BMEA -0.03
- Stochastic Oscillator
- STG 8.69
- BMEA 25.07
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.